| Jun 21 |
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
|
| Jun 17 |
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
|
| Jun 4 |
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 30 |
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
|
| May 29 |
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
|
| May 29 |
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
|
